Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cardio3 BioSciences brings in €7mm through its Series C venture round

Executive Summary

Heart therapy developer Cardio3 BioSciences SA grossed €7mm ($9.2mm) through what is believed to be its Series C venture round in which returning shareholders participated. The company concurrently raised €12mm through the conversion of existing convertible loans. The new money will be used to continue Phase III trials of C-Cure, which is designed to reprogram bone marrow cells into cardiopoietic cells that then grow new heart tissue to replace what has been damaged by heart failure.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies